Luvadaxistat is under clinical development by Neurocrine Biosciences and currently in Phase II for Cognitive Impairment Associated With Schizophrenia (CIAS). According to GlobalData, Phase II drugs for Cognitive Impairment Associated With Schizophrenia (CIAS) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Luvadaxistat LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Luvadaxistat overview

NBI-1065844 (TAK-831) is under development for the treatment of cognitive impairment associated with schizophrenia (CIAS). It is administered through oral route in the form of film coated tablet. The drug candidate is a new molecular entity (NME). It acts by targeting D-amino acid oxidase (DAAO). It was also under development for the treatment of cerebellar ataxia, negative symptoms and/or  and Friedrich ataxia.

Neurocrine Biosciences overview

Neurocrine Biosciences (Neurocrine) is a biopharmaceutical company that discovers, develops, and markets neurological drugs. The company’s lead product Ingrezza, is a vesicular monoamine transporter 2 (VMAT2) inhibitor to treat adults with tardive dyskinesia and chorea associated with Huntington’s disease. It is developing a pipeline of drug candidates for various indications in neurology, neuroendocrinology, and neuropsychiatry. Neurocrine also conducts clinical trials and studies for diseases such as movement disorders, epilepsy, and congenital adrenal hyperplasia, among others. The company works in collaboration with Mitsubishi Tanabe Pharma and AbbVie for products distribution. Neurocrine is headquartered in San Diego, California, the US.

For a complete picture of Luvadaxistat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.